<DOC>
	<DOCNO>NCT02698046</DOCNO>
	<brief_summary>This study design evaluate effectiveness oral iron therapy patient heart failure identify central peripheral mechanism involve improvement functional capacity intervention . The investigation include subjective objective measure exercise performance heart function intervention , tolerability oral iron treatment .</brief_summary>
	<brief_title>Oral Iron Therapy Chronic Heart Failure Patients</brief_title>
	<detailed_description>This placebo-controlled , double-blind randomized clinical trial include patient symptomatic stable chronic heart failure ( New York Heart Association Functional Class II III ) , diagnosis iron deficiency ( ferritin &lt; 100 ng / dL ferritin 100 - 300 ng / dL transferrin saturation &lt; 20 % ) follow outpatient clinic . The enrolled patient ( n = 36 ) randomly allocate ratio 2:1 treatment 60 mg elemental iron orally ( n = 24 ) placebo administration ( n = 12 ) , 3 time daily 4 month . The primary outcome investigated increase transferrin saturation ≥ 10 percentage point baseline intervention . Secondary outcome study change iron store , red blood cell index , neurohumoral activation , leave ventricular systolic function , functional capacity , mechanoreflex activity , quality life score .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion criterion Both gender patient age 18 year ; Diagnosis chronic heart failure ( identify use Framingham criterion ) ≥ 6 month ; New York Heart Association functional class II III ; Left ventricular ejection fraction ≤ 45 % Regular attendance outpatient Heart Failure Clinic ; Adequate therapeutic drug heart failure syndrome base betaadrenergic blocker , angiotensin convert enzyme inhibitor angiotensin receptor blocker , mineralocorticoid receptor blocker ; Evidence iron deficiency biochemical analysis : ferritin value &lt; 100 ng/dL 100 ng/dL 300 ng/dL , transferrin saturation &lt; 20 % ; Hemoglobin value 9,0 16 g/dL ; Provide write informed consent . Exclusion criterion Recent device implant ( last 3 month ) perspective device implantation ( conventional multisite pace ) next 6 month ; Known active infection , inflammatory disease Creactive protein &gt; 20 mg/dL Immunosuppressive therapy ; In use erythropoietin and/or current treatment oral intravenous iron ; Clinically bleed blood transfusion previous 3 month ; Renal failure dialysis ; Hemoglobinopathies , hemochromatosis active malignancy ; Unstable angina pectoris clinically significant uncorrected valvular disease , except mitral tricuspid regurgitation secondary ventricular dilatation ; Acute myocardial infarction acute coronary syndrome , transient ischaemic attack within last 3 month ; Uncontrolled arterial hypertension ; Evidence comorbidity feature active systemic disease , i.e . liver disease , collagen disease untreated hyperthyroidism hypothyroidism ; Pregnant lactate woman ; Anaemia due reason iron deﬁciency ( i.e . vitamin B12 deficiency ) ; Recent admission decompensated heart failure ( last 3 month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Iron</keyword>
	<keyword>Anemia</keyword>
	<keyword>Chronic disease</keyword>
</DOC>